2024 AACR | Abbisko Therapeutics will present 3 pre-clinical research results with oral presentation and posters

Abbisko Therapeutics will present FGFR4 inhibitor Irpagratinib (ABSK011) pre-clinical data with an oral presentation at the 2024 AACR Annual Meeting. In addition, its self-development innovation CSF-1R inhibitor Pimicotinib (ABSK021) and small molecule PD-L1inhibitor update data will also be published at AACR with poster board. Abbisko will present the following details at the 2024 AACR: Title: Selective FGFR4 inhibitor Irpagratinib (ABSK011) exhibits broad synergistic and combinatory anti-tumor effects with other therapeutic agents in preclinical HCC models Oral Presentation Number: 1228 Session Date and Time: 7 April, 2024, 3:05 PM - 3:20 PM Title: CSF-1R inhibition with Pimicotinib (ABSK021) enhanced anti-tumor efficacy of KRASG12C inhibitors in preclinical non-small cell lung cancer mouse models Poster Number: LB077 Poster Section： 54 Session Date and Time： 7 April, 2024, 1:30 PM - 5:00 PM Title: Cellular characterization of small molecule PD-L1 inhibitors reveal their novel mechanisms of action Poster Number： 2039 Poster Section： 27 Session Date and Time: 8 April, 2024, 9:00 AM - 12:30 PM

The release as fetched from its publisher. abbisko.com ↗